EPISODE · Jun 9, 2026 · 33 MIN
FDA To Review 12 Peptides: What It Means Moving Forward
from Redox Revolution · host William Seeds, MD
The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.Learn more about the SSRP Institute Follow for more!Instagram: @williamseedsmd | @redoxmedicalgroupYoutube: Subscribe Here
What this episode covers
The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next. Learn more about the SSRP Institute Follow for more! Instagram: @williamseedsmd | @redoxmedicalgroup Youtube:...
NOW PLAYING
FDA To Review 12 Peptides: What It Means Moving Forward
No transcript for this episode yet
Similar Episodes
No similar episodes found.